Author pages are created from data sourced from our academic publisher partnerships and public sources.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase…
Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations.… Expand
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-alpha), but CCgRs are rare. The mean CCgR rate is 13%,… Expand
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the… Expand
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
Nilotinib has a higher binding affinity and selectivity for BCR-ABL with respect to imatinib and is an effective treatment of chronic myeloid leukemia (CML) after imatinib failure. In a phase 2… Expand
Identification of risk factors in atypical chronic myeloid leukemia.
- M. Breccia, F. Biondo, R. Latagliata, I. Carmosino, F. Mandelli, G. Alimena
In the WHO classification atypical chronic myeloid leukemia (CML) has been considered as a new distinct clinical entity included in the category of mixed myeloproliferative/myelodysplastic disorders.… Expand
Long‐term survival of patients with acute myeloid leukemia
In 1982, the Fourth International Workshop on Chromosomes in Leukemia reviewed data prospectively collected on 716 patients with acute myeloid leukemia (AML) diagnosed between 1980 and 1982. The… Expand
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1.
- A. Shaw, P. Monaghan, +14 authors P. Mertens
- Biology, Medicine
- Journal of virological methods
- 1 November 2007
Since 1998, multiple strains of bluetongue virus (BTV), belonging to six different serotypes (types 1, 2, 4, 8, 9 and 16) have caused outbreaks of disease in Europe, causing one of the largest… Expand
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
The findings of this study suggest that imatinib mesylate at a daily dose of 600 mg is effective and safe in the short-term treatment of chronic myeloid leukemia in blast crisis, but does not… Expand
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study
Background:Optimal adherence to imatinib therapy is of paramount importance to maximise treatment effectiveness in patients with chronic myeloid leukaemia (CML). The main objective of this study was… Expand